reported that a patient with advanced pancreatic adenocarcinoma and BRAF V600E mutation who received treatment with dabrafenib plus trametinib, resulting in a marked decline in CA19–9 levels; however, the patient died of an acute abdomen after only 19 days of treatment (29). The gene discussed is BRAF; the disease is pancreatic adenocarcinoma.